Recent decades have witnessed remarkable strides in the realm of clinical research and treatment for Systemic Lupus Erythematosus (SLE) and Sjögren’s ...

HOUSE, PA — Johnson & Johnson has unveiled groundbreaking findings on nipocalimab, an investigational FcRn blocker, in a ...

The following is a summary of “Dual seropositive nonerosive lupus arthritis: rhupus or not?” published in the February 2025 ...

We constructed miniaturized autoantigen arrays to perform large-scale multiplex characterization of autoantibody responses directed against structurally diverse autoantigens, using submicroliter ...

On track to announce the primary endpoint result from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in ...

The strongest genetic risk is within the major histocompatibility complex (MHC). Since autoantibody presence defines specific clinical subgroups of IIM, we aimed to correlate serotype and genotype, to ...

Results IgG in serum (17) and/or CSF (16) from 25 patients yielded unique AIS-specific staining on murine central nervous system (CNS) tissue. An autoantibody specific for TRIM46 was identified by ...

In part 4 of our interview, we learn more about nipocalimab’s safety profile and how this investigative agent might address ...

An off-label prescription drug has been shown to help children with autism gain the ability to speak. Leucovorin is used for ...